Pharmaceutical company
Appears in 18 stories
Manufacturer of Cialis (tadalafil)
Men who take tadalafil daily for enlarged prostate symptoms were 22% more likely to develop glaucoma over five years than men who don't take the drug, a study of nearly 74,000 people found. The results, published in the British Journal of Ophthalmology, also showed higher rates of ocular hypertension and primary open-angle glaucoma.
Updated 4 days ago
Acquirer; integrating Merida into its immunology pipeline
Eli Lilly agreed to buy Merida Biosciences for up to $2.875 billion. The deal adds a platform that destroys the specific antibodies driving autoimmune disease instead of broadly suppressing the immune system. Merida's lead drug, MER511, is in early human testing for Graves' disease and thyroid eye disease.
Updated Sep 1
Maker of tirzepatide (Mounjaro, Zepbound); FDA approved Mounjaro for cardiovascular risk reduction in August 2026
The FDA approved tirzepatide (Mounjaro) on August 28 to lower the risk of heart attack, stroke, and cardiovascular death in adults with type 2 diabetes at high risk. The decision rests on SURPASS-CVOT, a 13,000-patient trial that found tirzepatide matched an older GLP-1 medicine, dulaglutide (Trulicity), on major heart events, with an estimated 8% lower rate.
Updated Aug 29
Partner in diagnostic development and maker of Kisunla
Alzheimer's diagnosis used to require a $5,000 brain scan or a painful spinal tap. As of August 2026, the FDA has cleared four blood tests for the disease, from Roche's Elecsys pTau217 to C2N's PrecivityAD2, approved for adults as young as 40.
Updated Aug 25
Acquirer
Eli Lilly agreed to buy AtaiBeckley for $6.75 a share in cash, about $2.8 billion, with up to $1 billion more if two drugs hit development targets. The purchase pulls one of the world's largest drugmakers into psychedelic medicine.
Updated Jul 16
Surpassing Novo Nordisk in GLP-1 market share with expanding product line
Kailera Therapeutics just pulled off the largest biotech initial public offering in history, raising $625 million and watching its shares surge 62.5% on the first day of trading. The company, founded less than two years ago with drugs licensed from a Chinese pharmaceutical firm, is now valued at roughly $3.5 billion — without a single approved product. That a startup built entirely around next-generation obesity drugs can command this kind of investor enthusiasm tells you where the pharmaceutical industry's center of gravity has shifted.
Updated May 31
Constructing $9B+ manufacturing campus at LEAP
Indiana committed over $23 billion in private investment to a 9,500-acre industrial district in Boone County farmland before solving a basic problem: where the water would come from. The state is advancing a $560 million plan to pipe up to 25 million gallons per day from Indianapolis. The water would supply Eli Lilly's $9 billion pharmaceutical campus and Meta's $10 billion data center complex, despite objections from Indianapolis lawmakers, environmental groups, and hundreds of property owners along the pipeline route.
Launched Foundayo, expanding oral GLP-1 market
For two years, the most effective weight-loss drugs on the market required a weekly injection, but that barrier is now falling. Eli Lilly began shipping Foundayo on April 6, 2026 — just five days after FDA approval in a record 50-day review — making it the first oral GLP-1 pill with no food or water restrictions. At $149/month (or $25 with insurance), it's 85% cheaper than injectables.
Updated May 30
Developing competing once-weekly insulin efsitora alfa
For 104 years, every insulin on the market has required at least one injection per day. On March 26, the FDA approved Awiqli, a once-weekly basal insulin from Novo Nordisk for adults with type 2 diabetes. That cuts basal insulin injections from 365 to 52 per year.
Manufacturer of Mounjaro and Zepbound; Novo Nordisk's primary GLP-1 competitor
More than 30 million Americans now take GLP-1 receptor agonist drugs like Ozempic and Wegovy to lose weight. A persistent concern has dogged the medications since their rise: that they burn through muscle along with fat, leaving patients weaker even as they get thinner.
Second-largest GLP-1 franchise; advancing oral formulation
The biggest knock against blockbuster weight-loss drugs like semaglutide is that up to 40% of weight lost is lean tissue (muscle and bone), not fat. New therapies entering trials target genes to spare muscle.
Launches first non-fasting oral GLP-1 for obesity, intensifying competition in weight loss market
For the first time, patients with acquired hypothalamic obesity have an FDA-approved treatment. On March 19, 2026, the FDA approved Imcivree (setmelanotide), which targets this rare condition affecting roughly 10,000 Americans whose hypothalamic damage from brain tumor surgery makes diet and exercise ineffective.
Actively pursuing GLP-1 addiction trials
Drugs designed to control blood sugar and shrink waistlines may also quiet the cravings that drive addiction. A March 4 BMJ study of more than 600,000 U.S. veterans found GLP-1 users were 14 percent less likely to develop a new substance use disorder.
Maker of tirzepatide; chief GLP-1 competitor
Patients on Ozempic and Wegovy typically lose about 15% of their body weight, then stall around 14 months in. On May 25, NIH researchers in Nature Metabolism reported what may be happening inside the brain to cause that stall, and a way to keep the drug working longer.
Updated May 25
Maker of tirzepatide (Mounjaro, Zepbound), included in the GLP-1 cohort
A study of more than 12,000 patients found that those taking GLP-1 weight-loss drugs were 38% to 50% less likely to progress to stage IV cancer in four obesity-linked cancers. Cleveland Clinic led the study. Researchers compared GLP-1 users — on drugs like Ozempic, Wegovy, and Mounjaro — against patients taking older diabetes pills.
Updated May 24
Developing AK-OTOF gene therapy through acquired subsidiary
Children born profoundly deaf can now hear their parents' voices. A single injection of gene therapy into the inner ear restored hearing in dozens of patients, moving genetic deafness from permanent disability to treatable condition. The effect is rapid—most patients recover hearing within weeks and retain it for at least two years.
Updated May 19
Reduced insulin prices by 70% in 2023
On January 1, 2026, nonprofit Civica Rx launched insulin glargine pens at $55 a box; California debuted its CalRx-branded insulin the same day at the same price. Both undercut branded products by up to 90%: no insurance forms, no rebates, no hidden markups, just one transparent price for anyone, in a market three pharmaceutical giants control with a 90% share.
Negotiating partner in BALANCE model
Medicare has been banned from covering weight loss drugs since 2003. CMS launched BALANCE in December 2025, a voluntary model offering $50-per-month Ozempic and Wegovy access for 10% of Medicare enrollees starting July 2026.
Updated May 16
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
